Method to reduce inflammatory response in transplanted tissue
The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A 2A adenosine receptor agonist. If no anti-pathogenic agent is known the A 2A agonist can be used alone to reduce inflammation, as may occur during infection with antibiotic resistant bacteria, or certain viruses such as those that cause SARS or Ebola. Optionally, the method includes administration of a type IV PDE inhibitor.
1. A therapeutic method for treating inflammation caused by an immune response to transplanted tissue, comprising the administration to a patient in need thereof an effective amount of an A 2A adenosine receptor agonist, wherein the A 2A adenosine receptor agonist is a compound of formula (I):
wherein
Z is CR 3 R 4 R 5 ;
each R 1 is hydrogen;
each R 2 is hydrogen;
R 3 is hydrogen;
R 4 and R 5 together with the atom to which they are attached form a saturated mono- or bicyclic cycloalkyl ring having 3, 4, 5, 6, 7, 8, 9 or 10 ring atoms wherein the cycloalkyl optionally comprises 1-2 N, O, or S;
wherein any ring comprising R 4 and R 5 is substituted with from 1 to 3 R 6 groups; wherein each R 6 is independently (C 1 -C 6 )alkyl, CH 2 OH, —CO 2 R a ,R a C(═O)O—, or R b R c NC(═O)—;
wherein any of the alkyl groups of R 6 is optionally substituted on carbon with a substituent selected from the group consisting of CH 2 OH, —CO 2 R a ,R a C(═O)O—, and R b R c NC(═O)—;
each R 7 is independently hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, phenyl or phenyl(C 1 -C 3 )alkylene;
X is —CH 2 OH, —CO 2 R a , —OC(O)R a , —CH 2 OC(O)R a , or—C(O)NR b R c ;
each R a , R b and R c is independently hydrogen, (C 1 -C 6 )alkyl, or (C 1 -C 6 )alkyl substituted with 1-3 (C 1 -C 6 )alkoxy, (C 3 -C 6 )cycloalkyl, (C 1 -C 6 )alkylthio, aryl or aryl (C 1 -C 6 )alkylene; and
m is 0 to 6;
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the immune response is a transplant rejection, or graft versus host disease.
3. The method of claim 2 , wherein the immune response is a transplant rejection.
4. The method of claims 1 or 2 , wherein the transplantation comprises an organ, tissue or cell transplantation.
5. The method of claim 4 , wherein the cells are bone marrow, skin, or pancreatic islets.
6. The method of claim 5 , wherein the cells are pancreatic islets.
7. The method of claim 4 , wherein the organ is a cornea, kidney, lung, liver, or heart.
8. The method of claim 1 , wherein the ring comprising R 4 , R 5 and the atom to which they are connected is cyclopentane, cyclohexane, piperidine, piperazine, decaline, hexahydro-pyrimidine, imidazolidine, or pyrazolidine.
9. The method of claim 8 , wherein the ring comprising R 4 , R 5 and the atom to which they are connected is cyclopentane, cyclohexane, piperidine, piperazine, hexahydro-pyrimidine, imidazolidine, or pyrazolidine.
10. The method of claim 9 , wherein the ring comprising R 4 and R 5 and the atom to which they are connected is cyclohexane, piperidine or piperazine.
11. The method of claim 1 , wherein R 6 is —CO 2 R a , R a C(═O)O—, or R b R c NC(═O) —.
12. The method of claim 1 , wherein R 6 is methyl, ethyl, t-butyl, —CO 2 R a or CONR b R c .
13. The method of claim 1 , wherein R 6 is —CH 2 OH, —CH 2 OAc, -or CH 2 C(═O)OCH 3 .
14. The method of claim 1 , wherein R a and R b are independently hydrogen, methyl, ethyl, phenyl or benzyl.
15. The method of claim 1 , wherein R a is (C 1 -C 6 )alkyl.
16. The method of claim 1 , wherein R a is methyl, ethyl, propyl or butyl.
17. The method of claim 1 , wherein R a is, methyl, ethyl, i-propyl, i-butyl or tert-butyl.
18. The method of claim 1 , wherein R 7 is hydrogen, or alkyl.
19. The method of claim 1 , wherein R 7 is hydrogen, methyl or ethyl.
20. The method of claim 19 , wherein R 7 is H, or methyl.
21. The method of claim 1 , wherein N(R 7 ) 2 is amino, methylamino, dimethylamino; ethylamino; pentylamino, diethylamino or benzylamino.
22. The method of claim 1 , wherein N(R 7 ) 2 is amino, or methylamino.
23. The method of claim 1 , wherein X is —CH 2 OH or —C(O)NR b R c .
24. The method of claim 23 , wherein X is —C(O)NHCH 2 CH 3 .
25. The method of claim 1 , wherein m is 1 or 2.
26. The method of claim 1 , wherein the rings comprising R 4 , R 5 and the atom to which they are connected are selected from the group consisting of:
where m is from 1 to 3.
27. The method of claim 1 , wherein the rings comprising R 4 , R 5 and the atom to which they are connected are selected from the group consisting of:
28. The method of claim 1 , wherein the ring comprising R 4 and R 5 is 2-methylcyclohexane, 2,2-dimethylcyclohexane, 2-ethylcyclohexane, 2,2-diethylcyclohexane, 2-tert-butylcyclohexane, 3-methylcyclohexane, 3,3-dimethylcyclohexane, 4-methylcyclohexane, 4-ethylcyclohexane, 4-tert-butylcyclohexane, 4-carboxymethyl cyclohexane, 4-carboxyethyl cyclohexane, 3,3,5,5-tetramethyl cyclohexane, 2,4-dimethyl cyclopentane, 4-cyclohexanecarboxylic acid, or 4-cyclohexanecarboxylic acid esters.
29. The method of claim 1 , wherein the ring comprising R 4 and R 5 is 4-piperidine, 4-piperidene-1-carboxylic acid, 4-piperidine-1-carboxylic acid methyl ester, 4-piperidine-1-carboxylic acid ethyl ester, 4-piperidine-1-carboxylic acid propyl ester, 4-piperidine-1-carboxylic acid tert-butyl ester, 3-piperidine, 3-piperidene-1-carboxylic acid, 3-piperidine-1-carboxylic acid methyl ester, or 3-piperidine-1-carboxylic acid tert-butyl ester.
30. The method of claim 1 , wherein the A 2A adenosine receptor agonist is:
31. The method of claim 1 , wherein the A 2A adenosine receptor agonist is
32. The method of claim 31 , wherein the A 2A adenosine receptor agonist is the compound:
33. The method of claim 1 , wherein the A 2A adenosine receptor C agonist is administered by operation of a pump.